Borgioli M, Merendino E, Ricci B
Arzneimittelforschung. 1979;29(8a):1311-6.
10-Methoxy-1,6-dimethyl-ergolin-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) administered intravenously (8 mg) in a group of 10 healthy subjects caused a reduction of the arm-retina circulation time and a reduction of the ocular tone. The therapeutic effectiveness in 37 patients with various eye diseases was tested by administering nicergoline p.o. at a dose of 30 mg/day for 30 days and 20 mg/day as maintenance dose for 60-120 days. Positive results, in various percentages, were observed in cases of arterial obstructions, venous thrombosis, diabetic retinopathies, senile macular degenerations, papilla ischaemic oedema, central serous chorioretinopathies. Nicergoline caused no subjective or objective undesired effects.
在一组10名健康受试者中静脉注射10 - 甲氧基 - 1,6 - 二甲基 - 麦角灵 - 8β - 甲醇 -（5 - 溴烟酸酯）（尼麦角林，喜得镇）8毫克，可使手臂 - 视网膜循环时间缩短，并降低眼压。通过口服尼麦角林对37例患有各种眼部疾病的患者进行治疗效果测试，剂量为30毫克/天，持续30天，维持剂量为20毫克/天，持续60 - 120天。在动脉阻塞、静脉血栓形成、糖尿病视网膜病变、老年性黄斑变性、乳头缺血性水肿、中心性浆液性脉络膜视网膜病变等病例中观察到了不同比例的阳性结果。尼麦角林未引起主观或客观的不良影响。
